Arca
Skip to content
Tools
Tools

AKT1: RAC-alpha serine/threonine-protein kinase

AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis.

  • Drugs that act on it: 3
  • Approved: 0
  • In phases 1 to 3: 3
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on AKT1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 3

Approved0

    Phase 30

      Phase 21

      • Rupitasertib

      Phase 12

      • BAY-1125976
      • SR-13668

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Serine/threonine-protein kinase AKT inhibitor.
      RupitasertibPhase 2Merck KGaASmall moleculeInhibitor0
      BAY-1125976Phase 1BayerSmall moleculeInhibitor0
      SR-13668Phase 1—Small moleculeInhibitor0

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Proteus syndrome0.76
      • Cancer0.67
      • Cowden syndrome 60.66
      • Breast adenocarcinoma0.65
      • Breast carcinoma0.63
      • Colorectal adenocarcinoma0.62
      • Ovarian carcinoma0.59
      • Clear cell renal carcinoma0.51
      • Neoplasm0.47
      • Neurodegenerative disease0.47

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4282, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P31749, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.